Pro-Dex (NASDAQ:PDEX) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of Pro-Dex (NASDAQ:PDEX) from a buy rating to a strong-buy rating in a report published on Saturday.

Separately, Ascendiant Capital Markets upped their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Pro-Dex Stock Down 0.6 %

Pro-Dex stock opened at $49.44 on Friday. Pro-Dex has a 12 month low of $16.18 and a 12 month high of $54.84. The stock has a market capitalization of $161.17 million, a PE ratio of 32.10 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The business has a 50 day simple moving average of $40.23 and a 200-day simple moving average of $27.96.

Insider Buying and Selling at Pro-Dex

In other news, CFO Alisha Charlton sold 1,000 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the completion of the sale, the chief financial officer now directly owns 15,339 shares in the company, valued at $613,866.78. This represents a 6.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 47.50% of the company’s stock.

Institutional Trading of Pro-Dex

Several large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Renaissance Technologies LLC lifted its position in Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares in the last quarter. Bard Associates Inc. boosted its stake in Pro-Dex by 17.6% during the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the last quarter. FMR LLC grew its holdings in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.